Denovo Biopharma

Denovo Biopharma is a San Diego and Beijing-based biotech with a disruptive 'asset regeneration' strategy. It in-licenses failed or shelved late-stage drug candidates and applies its proprietary genomics platform to discover novel predictive biomarkers from residual clinical trial samples. By using these biomarkers as companion diagnostics to select responsive patients in new, smaller trials, Denovo aims to de-risk and accelerate the development of personalized medicines in oncology and neuroscience at a fraction of the traditional cost and time. The company is privately held and has advanced several programs into late-stage global trials.

Proprietary biomarker discovery platform that analyzes residual clinical trial samples (e.g., plasma DNA) using whole-genome scanning to identify genetic biomarkers (SNPs) predictive of drug response. This enables the resurrection of failed late-stage drug candidates for biomarker-selected patient populations.

Denovo occupies a unique niche in 'drug resurrection' via biomarker discovery. While many companies develop companion diagnostics for their own drugs, few focus exclusively on rescuing failed candidates. Potential competitors include other biotechs with strong biomarker platforms (e.g., BridgeBio's affiliate companies, some precision oncology firms) and large pharma internal efforts, but Denovo's specialized, agnostic platform and capital-efficient partnership model provide distinct differentiation.